Editas Medicine
在场
高管
查看带有其 20 名主要高管的组织结构图
Editas Medicine 搜索最多的简介
- Gilmore O'Neill, Chief Executive Officer and President
- Andrew Hirsch, Director
- Meeta Chatterjee, Director
高管在Editas Medicine变化
- Harry Gill, Senior Vice President, Operations, 已经离开公司 (新闻发布的2024一月3号).
- Bruce Eaton, Executive Vice President, Chief Technology Officer and Chief Business Officer, 将于 20241月2 退休 (新闻发布的2023十月12号).
- Caren Deardorf已作为Chief Commercial and Strategy Officer加入公司 (新闻发布的2023九月26号).
创建提醒
跟踪 Editas Medicine 的高管变动
生物技术
Editas Medicine 拥有 2,289 家竞争者，其中包括 Lonza (瑞士)、Eurofins (卢森堡) 和 Adaptive Phage Therapeutics (美国(美洲))。
Popular M&A news in 生物技术
- Attovia Therapeutics 刚刚宣布为 150 筹款数百万美元。 (公布2024五月14号).
- Bruker has announced the acquisition of NanoString Technologies (公布2024五月13号).
- Aardvark Therapeutics 刚刚宣布为 85 筹款数百万美元。 (公布2024五月12号).
生物技术 行业的其他推荐联系人
消息
Editas Medicine 的最新新闻稿
- Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration | Editas Medicine
- Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events | Editas Medicine
- Editas Medicine Announces First Quarter 2024 Results and Business Updates | Editas Medicine
- Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting | Editas Medicine
- Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting | Editas Medicine
- Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar | Editas Medicine
- Editas Medicine Announces Third Quarter 2023 Results and Business Updates | Editas Medicine
- Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events | Editas Medicine
- Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer | Editas Medicine
- Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer | Editas Medicine
- View more press releases Close
通过电子邮件
